← Back to Clinical Trials
Recruiting NCT04527419

SLND or Not in cT1 GGO Invasive Lung Adenocarcinoma (ECTOP-1009)

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Carcinoma, Non-Small-Cell Lung
Sponsor Fudan University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 545
Sex ALL
Min Age 18 Years
Max Age 75 Years
Start Date 2022-02-09
Completion 2026-07-21
Interventions
No mediastinal lymph node dissection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a study from Eastern Cooperative Thoracic Oncology Project, numbered as ECTOP-1009. Systematically mediastinal lymph node dissection or not in clinical stage T1 ground-glass dominated invasive lung adenocarcinoma: a multi-center, prospective clinical trial

Eligibility Criteria

Inclusion Criteria: * Clinical stage T1N0M0 and planned curative surgery. * A single lesion detected on computed tomography (CT) scan featured as ground glass nodule(GGO) and C/T ratio ≤0.5. * Age 18 to 75. * Patients who have signed the informed consent form. Exclusion Criteria: * Other than invasive adenocarcinoma by pathological analysis. * Patients undergoing wedge resection but not meeting the specific conditions of a Consolidation/Tumor Ratio (CTR) ≤ 0.25 AND a maximum tumor diameter ≤ 2 cm, based on the oncological outcomes of the JCOG0804/WJOG4507L trial. * Not complete resected or curative intent. * Patients who have history of other malignant tumors. * Patients who have history of thoracic surgery. * Patients who have received radiation, chemotherapy or other treatments previously.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}